BridgeBio nabs Priority Review for infigratinib for achondroplasia

RegulatoryinfigratinibPositive

AI Analysis

Summary

BridgeBio received Priority Review designation from the FDA for infigratinib in the treatment of achondroplasia, accelerating the regulatory timeline for this rare genetic disorder therapy.

Outcome Details

Priority Review granted

Importance:7/10

Sentiment:

0.70

regulatorypriority reviewachondroplasiarare disease

Related Companies

$BBOT

Read the original article

Published by Seeking Alpha Healthcare on October 6, 2026 2:53 PM

Read Original